Sakar Healthcare Share Rises After Q2 Results: Up Over 500% in 5 Years, Will the Rally Continue? Check Target and Stop Loss

The Sakar Healthcare share price is up about 8.7% on Monday after a results-day swing that saw the stock open higher, touch Rs 1,019 and end lower on Friday. Whether the Sakar Healthcare share rally continues depends on whether the profit and margin gains in the Q2 numbers can be repeated, and on whether the stock can clear the resistance levels set out below.

I could not retrieve an expert Sakar Healthcare share price target or stop loss for this stock, and I found no brokerage coverage with price targets, so the levels here come from indicators and price history. This article covers the day's move, the Q2 numbers, the five-year run, valuation, shareholding, technical levels and risks. It is educational and not advice.

Click Here – Get Free Investment Predictions

Sakar Healthcare Share Price Today: Rebound After a Results-Day Swing

Sakar Healthcare share: measure (NSE, about 2:54 PM)	Reading
Last price	Rs 966.80, up 8.65%
Previous close (23 Oct)	Rs 889.80, down 6.51% that day
Open	Rs 885.00
Day high	Rs 972.00
Volume	About 1.72 lakh shares
52-week high and low	Rs 1,229.85 and Rs 352
Distance from 52-week high	About 21.4% below (my calculation)
Distance from 52-week low	About 174.7% above (my calculation)

Sakar Healthcare share: session (2026)	Close (Rs)	Change	Volume (shares)
19 Oct	923.20	Down 4.0%	66,081
21 Oct	904.80	Down 2.0%	2,02,977
22 Oct	951.80	Up 5.2%	1,27,832
23 Oct (results)	889.80	Down 6.5%	7,47,090
26 Oct (about 2:54 PM)	966.80	Up 8.65%	1,71,872

Friday was the heavy session. The Sakar Healthcare share opened at Rs 956, rose to Rs 1,019 after the results were filed and then fell to a low of Rs 855.70 before closing at Rs 889.80. Volume of 7.47 lakh shares was about 5.4 times the average of the previous eight sessions (my calculation), so the move was driven by real trading and not by a thin market.

Monday's rebound in the Sakar Healthcare share is sharper than the 4.5% quoted in the source headline, which was an earlier reading. The figures in that headline also do not match exchange data on the open and the previous close, so I use data provider prices throughout. At Rs 966.80 the stock has recovered all of Friday's fall and is about 27.6% below its September peak of Rs 1,229.85 when measured from Friday's close (my calculation).

Track small-cap healthcare stocks on the Univest screeners page

Sakar Healthcare Q2 Results: Revenue, Profit and Margin

Sakar Healthcare Q2 FY27 item	Q2 FY27	Comparison
Revenue from operations	Rs 87.42 crore	Rs 57.56 crore a year ago, up 51.9%; about 19.8% above Q1 (my calculation)
EBITDA	About Rs 24.6 crore	Margin about 28%; about 19.7% a year ago
Profit before tax, before exceptional items	Rs 16.02 crore	Not stated for last year
Depreciation	Rs 6.60 crore	Not stated for last year
Finance costs	Rs 2.00 crore	Not stated for last year
Net profit	Rs 11.31 crore	Rs 4.54 crore a year ago, up about 149%; Rs 10.28 crore in Q1, up about 10% (my calculation)
Net profit margin	About 12.9%	About 7.9% a year ago (my calculation)

The Sakar Healthcare Q2 results show profit growing almost three times as fast as revenue, which is the sign of operating gearing. Revenue rose Rs 29.9 crore and EBITDA rose by about Rs 13 crore (my calculation, using the 19.7% margin a year ago), so a large share of every extra rupee of sales reached profit. The EBITDA margin figures differ slightly between sources, at about 27.9% to 28.2%, because of definitions, and I use about 28%.

Net profit grew only about 10% from Q1 against revenue growth of about 19.8%, because depreciation and finance costs take a combined Rs 8.6 crore of the Rs 24.6 crore EBITDA (my calculation). That is the point to watch for the Sakar Healthcare share. If the company keeps adding capacity, the cost of financing and depreciating it will limit how much of the margin gain reaches profit.

What Drove the Quarter for the Sakar Healthcare Share: Oncology Mix and Operating Gearing

Driver cited by the company	What it means
New oncology approvals	More products can be sold in more markets
Strong demand across geographies	Growth is not limited to one region
Better oncology mix	Higher-value products lift the margin
Operating gearing	Fixed costs are spread over higher sales
Cost management	Expenses grew slower than revenue

Managing Director Sanjay Shah described Q2 as a quarter of meaningful progress for the oncology business, and the drivers above are the ones the company named. The pharma exposure is narrow, so the Sakar Healthcare share depends heavily on how many oncology products it can approve and sell. Regulatory approvals are lumpy, which means growth can be uneven from quarter to quarter.

The company gave no outlook or guidance in the reports I retrieved, and no earnings call transcript was available. Without guidance, the market is left to extrapolate from one quarter, and that is one reason the Sakar Healthcare share swung so sharply on results day.

The 5-Year Run: How Far the Sakar Healthcare Share Has Come

Sakar Healthcare share: period	Start (Rs)	Now (Rs)	Change (my calculation)
Five years (week of 25 Oct 2021)	153.35	966.80	Up about 531%
One year (week ending 31 Oct 2025)	361.20	966.80	Up about 168%
From the 52-week low	352.00	966.80	Up about 175%
From the 52-week high (week of 21 Sep 2026)	1,229.85	966.80	Down about 21.4%

The Sakar Healthcare share's five-year return is real, but it came in bursts and from a low base. The share was near Rs 150 in late 2021, drifted lower in 2022, rose through 2023 and 2024 and then moved from about Rs 520 in March to a peak near Rs 1,230 in September 2026. That means most of the gain arrived in the past eight months, and past returns say nothing about future ones.

The Sakar Healthcare share has risen so far that it also carries the risk of sharp pullbacks. It is already 21.4% below its September peak, and it fell about 27.6% from that peak to Friday's close (my calculation), so even a strong quarter did not stop the slide on results day.

Valuation and Shareholding of Sakar Healthcare

Sakar Healthcare share: valuation (data provider)	Reading
Market capitalisation at Friday's close	Rs 1,980 crore; about Rs 2,150 crore at Rs 966.80 (my calculation)
Trailing price to earnings	46.18; about 50.2 at Rs 966.80 (my calculation)
Industry price to earnings	35.66
Book value per share	Rs 155.50
Price to book	5.72; about 6.2 at Rs 966.80 (my calculation)
Return on equity	12.39%
Debt to equity	0.13
Dividend yield	0.00%

Sakar Healthcare share: shareholding	Sep 2025	Jun 2026	Sep 2026
Promoters	52.86%	52.52%	51.70%
Foreign institutions	13.31%	12.13%	12.34%
Domestic institutions	Not split in the feed	11.37%	11.92%
Public	33.84%	23.98%	24.04%

The Sakar Healthcare share trades at a premium to its sector on trailing earnings, and the price to book of about 6.2 is high against a return on equity of 12.39%. The market is paying for growth that the Q2 numbers support, but not yet for growth that is proven over several quarters. Debt to equity of 0.13 is low, which gives the company room to borrow for expansion.

Promoter holding fell to 51.70% in September 2026 from 52.52% in June and 52.86% a year earlier, a fall of about 1.16 percentage points over the year (my calculation). The sources I used do not say why, so I cannot call it a sale or a dilution. As of June 2026, promoter Sanjay S Shah held 44.98%, Tata Capital Healthcare Fund II held 10.38%, HBM Healthcare Investments held 6.74% and Cobra India held 3.94%.

Technical Levels and Stop Loss Zones for the Sakar Healthcare Share

Sakar Healthcare share: indicator (daily)	Reading
14-day RSI	About 46.6, neutral
20-day EMA	About Rs 990.85, 2.4% above the price (my calculation)
50-day average	About Rs 1,011.74, 4.4% above the price (my calculation)
SuperTrend	Sell; upper band Rs 1,120.46, lower band Rs 802.28
MACD	Minus 32.3 against a signal of minus 21.4, negative
ADX and directional lines	ADX 52.8; plus DI 10.9, minus DI 21.4, a down trend
Bollinger bands	Lower Rs 868.02, middle Rs 1,007.51, upper Rs 1,146.99
Average true range	About Rs 75.46 a day, about 7.8% of the price (my calculation)

Sakar Healthcare share: level for stop loss and target planning	Rs	What it marks
Resistance 3	1,120.46	SuperTrend upper band
Resistance 2	1,011.74	50-day average
Resistance 1	990.85	20-day EMA, just above Monday's high of Rs 972
Support 1	889.80	Friday's close
Support 2	868.02	Lower Bollinger band
Support 3	855.70	Friday's low

The daily trend of the Sakar Healthcare share is still down, though the RSI near 46.6 is neutral and not oversold. The price sits under both averages and under the SuperTrend upper band, and Monday's high of Rs 972 stopped just short of the 20-day EMA at Rs 990.85. A close above that average and then above Rs 1,011.74 would be the first sign that the rebound has turned into a trend change.

For anyone planning a Sakar Healthcare stop loss, the zone between Rs 855.70 and Rs 889.80 is the one traders will watch, and a close below Rs 855.70 would mean the post-results rebound has failed. The stock moves about Rs 75 a day on average, or 7.8% of its price, so a tight stop can be hit by ordinary movement. Any Sakar Healthcare stop loss should match your own risk limit, and these readings are not recommendations.

Download the Univest iOS App or Univest Android App to track Sakar Healthcare and other small-cap stocks.

Will the Sakar Healthcare Rally Continue? A Framework by Investor Type

Investor type	Things to weigh	What to check
Long-term investor	Profit growth of about 149% and a wider margin against a price to earnings near 50	Whether the next two quarters hold the margin near 28%
Short-term trader	A rebound inside a down trend with resistance near Rs 991 to Rs 1,012	Support near Rs 856 to Rs 890 and volume
Existing holder	Five-year gains, but a 21% drop from the peak	Your entry price, position size and risk limit

None of these rows is a recommendation. I found no Sakar Healthcare share price target from experts, and a small-cap with a market value near Rs 2,150 crore can swing sharply on volume. Treat the Sakar Healthcare share as a stock that needs a margin of safety in position size.

Risks to Check Before You Act on the Sakar Healthcare Share

1. Concentration. For the Sakar Healthcare share, oncology drives the story, and delays in product approvals would hit growth.
2. Valuation. For the Sakar Healthcare share, a price to earnings near 50 leaves little room for a weak quarter.
3. Volatility. The Sakar Healthcare share moved minus 6.5% on Friday and plus 8.65% on Monday, and it averages about 7.8% a day.
4. Promoter stake. For the Sakar Healthcare share, the promoter holding has fallen about 1.16 points in a year, and the reason is not stated in the sources I used.
5. Liquidity. For the Sakar Healthcare share, volume of a few lakh shares a day can make exits difficult in a fall.

Conclusion

The Sakar Healthcare share rose about 8.7% on Monday after Q2 profit of Rs 11.31 crore, up about 149%, and a margin near 28%. The five-year gain of about 531% in the Sakar Healthcare share is large, but the daily trend is still down and the valuation is full, so check the oncology pipeline, watch the levels near Rs 856, Rs 890 and Rs 991, and decide according to your own risk profile.

Frequently Asked Questions

Why did the Sakar Healthcare share rise after the Sakar Healthcare Q2 results?

Ans. Q2 FY27 net profit rose to Rs 11.31 crore from Rs 4.54 crore a year ago on revenue of Rs 87.42 crore, up 51.9%. The EBITDA margin widened to about 28% from about 20%, which the company linked to new oncology approvals, a better mix, operating gearing and cost control. The stock traded near Rs 966.80 around 2:54 PM, up 8.65%.

What is the Sakar Healthcare share price target?

Ans. I could not find any brokerage or expert target for the stock, so I do not give one. On daily indicators, resistance is near Rs 990.85, Rs 1,011.74 and Rs 1,120.46. Please check your own research and any registered adviser's view before you decide.

Where is a sensible Sakar Healthcare stop loss zone?

Ans. Traders watch the zone between Rs 855.70, Friday's low, and Rs 889.80, Friday's close, with the lower Bollinger band at Rs 868.02 in between. The stock moves about Rs 75 a day on average, so tight stops can be hit by normal movement. Any stop loss should match your own risk limit, and this is not a recommendation.

Has the Sakar Healthcare share really risen 500% in five years?

Ans. Using weekly closes, the share rose from Rs 153.35 in the week of 25 Oct 2021 to about Rs 966.80, a gain of about 531% (my calculation). Most of that gain came in the past eight months, and the stock is about 21.4% below its 52-week high of Rs 1,229.85. Past returns do not predict future returns.

Is the Sakar Healthcare share overvalued?

Ans. The data provider shows a trailing price to earnings of 46.18 against an industry level of 35.66, and a price to book of 5.72, with a return on equity of 12.39%. At Rs 966.80 those become about 50.2 and 6.2 (my calculation). That is a premium valuation, so it depends on growth continuing.

What changed in the Sakar Healthcare shareholding?

Ans. Promoter holding was 51.70% in Sep 2026, down from 52.52% in Jun 2026 and 52.86% in Sep 2025. Foreign institutions held 12.34% and domestic institutions 11.92%. The sources I used do not give the reason for the fall in promoter holding.

Is this Sakar Healthcare share article investment advice?

Ans. No. This article is educational. Prices, ratios, results and levels come from company filings, news reports and data providers and may change. Please check the facts and your own risk profile before you invest.

Is this article investment advice?

Ans. No. It is educational and not a recommendation to buy or sell. Please check the figures against company filings and your own risk profile before you act on anything you read here.